December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
New data for CC-486 maintenance therapy in AML support a new escalated 21-day dosing schedule for patients who experience relapse with ≤ 15% blasts and an overall preservation of health-related quality of life.